Recent advances and future strategies in first-line treatment of ES-SCLC
Gomez-Randulfe, Igor Leporati, R. Gupta, B. Liu, S. P. Califano, Raffaele
Gomez-Randulfe, Igor
Leporati, R.
Gupta, B.
Liu, S. P.
Califano, Raffaele
Citations
Altmetric:
Abstract
Recent advancements in treating extensive-stage small-cell lung cancer (ES-SCLC) have been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based chemotherapy, leading to modest yet notable improvements in patient outcomes, which become more evident with longer follow-up. However, critical challenges persist, such as identifying effective biomarkers for accurate patient selection or finding more effective drugs. This review delves into the current and evolving treatment landscape for ES-SCLC, focusing on the most promising therapeutic strategies under investigation. We discuss the latest developments in the use of newer ICIs, antiangiogenic agents, PARP inhibitors (PARPi), lurbinectedin, and anti-DLL3 agents, offering insights into potential future directions in the management of this aggressive cancer.
Description
Date
2024
Publisher
Collections
Keywords
Type
Article
Citation
Gomez-Randulfe I, Leporati R, Gupta B, Liu SP, Califano R. Recent advances and future strategies in first-line treatment of ES-SCLC. EUROPEAN JOURNAL OF CANCER. 2024 MAR;200. PubMed PMID: WOS:001175568300001. English.